PI3K/AKT信号通路在2型糖尿病患者种植体骨结合中作用机制的研究进展

doi:10.13591/j.cnki.kqyx.2022.11.013

摘要/Abstract

摘要： 口腔种植治疗目前被认为是缺牙患者的首选治疗方案,但糖尿病仍然是种植治疗的相对禁忌证。糖尿病患者的高血糖环境以及微血管病变等可能会影响成骨细胞及破骨细胞的功能,影响骨代谢,导致种植失败。目前,对于糖尿病影响种植体骨结合的确切机制尚未阐明。PI3K/AKT信号通路在骨组织代谢中起重要作用,可促进成骨细胞的增殖和分化;此外,PI3K/AKT/mTOR也是响应胰岛素信号传导的经典途径。该文分别对PI3K/AKT信号通路在2型糖尿病和种植体骨结合中作用机制的研究进展进行综述,为今后促进糖尿病患者种植体周围骨再生等研究奠定基础。

关键词: PI3K/AKT, 2型糖尿病, 种植体骨结合, 胰岛素抵抗, 成骨分化

Abstract: Oral implantation is currently considered as the preferred treatment for patients with tooth loss, but diabetes is still a relative contraindication for implant therapy. The hyperglycemic environment and microvascular lesions of diabetic patients may affect osteoblasts, their functions and bone metabolism, leading to implant failure. At present, the mechanism of diabetes affecting binding between implant and bone has not been clarified. PI3K/AKT signaling pathway plays an important role in bone tissue metabolism and can promote the proliferation and differentiation of osteoblasts. In addition, PI3K/AKT/mTOR is also a classic pathway responding to insulin signaling. This paper reviews progress of research on the mechanism of PI3K/AKT signaling pathway in type 2 diabetes and implant osseointegration, respectively, which may lay a good foundation for future research on promoting peri-implant bone regeneration in diabetic patients.

Key words: PI3K/AKT, type 2 diabetes mellitus, implant osseointegration, insulin resistance, osteogenic differentiation

中图分类号:

R780.2

董硕, 汤春波. PI3K/AKT信号通路在2型糖尿病患者种植体骨结合中作用机制的研究进展[J]. 口腔医学, 2022, 42(11): 1026-1030.

DONG Shuo, TANG Chunbo. Progress of research on the mechanism of PI3K/AKT signaling pathway in implant osseointegration in patients with type 2 diabetes mellitus[J]. Stomatology, 2022, 42(11): 1026-1030.

参考文献

[1] Li GW, Prior JC, Leslie WD, et al. Frailty and risk of fractures in patients with type 2 diabetes[J]. Diabetes Care, 2019, 42(4):507-513.
[2] Henderson S, Ibe I, Cahill S, et al. Bone quality and fracture-healing in type-1 and type-2 diabetes mellitus[J]. J Bone Joint Surg Am, 2019, 101(15):1399-1410.
[3] Wang LX, Gao ZH, Liu CY, et al. Potential biomarkers of abnormal osseointegration of implants in type Ⅱ diabetes mellitus[J]. BMC Oral Health, 2021, 21(1):583.
[4] Li L, Sun Y, Zhang YN, et al. Mutant huntingtin impairs pancreatic β-cells by recruiting IRS-2 and disturbing the PI3K/AKT/FoxO1 signaling pathway in Huntington's disease[J]. J Mol Neurosci, 2021, 71(12):2646-2658.
[5] Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer:Biological and therapeutic significance[J]. Semin Cancer Biol, 2019, 59:147-160.
[6] Teng Y, Fan YB, Ma JW, et al. The PI3K/Akt pathway:Emerg-ing roles in skin homeostasis and a group of non-malignant skin disorders[J]. Cells, 2021, 10(5):1219.
[7] Zaryouh H, de Pauw I, Baysal H, et al. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combina-tion with EGFR-targeting agents to treat head and neck squamous cell carcinoma[J]. Med Res Rev, 2022, 42(1):112-155.
[8] Massacesi C, di Tomaso E, Fretault N, et al. Challenges in the clinical development of PI3K inhibitors[J]. Ann N Y Acad Sci, 2013, 1280(1):19-23.
[9] Castillo SD, Vanhaesebroeck B, Sebire NJ. Phosphoinositide 3-kinase:A new kid on the block in vascular anomalies[J]. J Pathol, 2016, 240(4):387-396.
[10] Franke TF, Kaplan DR, Cantley LC, et al. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate[J]. Science, 1997, 275(5300):665-668.
[11] Murthy SS, Tosolini A, Taguchi T, et al. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization[J]. Cytogenet Cell Genet, 2000, 88(1/2):38-40.
[12] Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha[J]. Curr Biol, 1997, 7(4):261-269.
[13] Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex[J]. Science, 2005, 307(5712):1098-1101.
[14] Manning BD, Cantley LC. AKT/PKB signaling:Navigating downstream[J]. Cell, 2007, 129(7):1261-1274.
[15] Kousteni S. FoxO1, the transcriptional chief of staff of energy metabolism[J]. Bone, 2012, 50(2):437-443.
[16] Li XH, Monks B, Ge QY, et al. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator[J]. Nature, 2007, 447(7147):1012-1016.
[17] Hay N. Interplay between FOXO, TOR, and Akt[J]. Biochim Biophys Acta, 2011, 1813(11):1965-1970.
[18] Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B[J]. Nature, 1995, 378(6559):785-789.
[19] Buzzi F, Xu LH, Zuellig RA, et al. Differential effects of protein kinase B/Akt isoforms on glucose homeostasis and islet mass[J]. Mol Cell Biol, 2010, 30(3):601-612.
[20] Manning BD, Toker A. AKT/PKB signaling:Navigating the network[J]. Cell, 2017, 169(3):381-405.
[21] Yue JTY, Lam TKT. Lipid sensing and insulin resistance in the brain[J]. Cell Metab, 2012, 15(5):646-655.
[22] Huang XJ, Liu GH, Guo J, et al. The PI3K/AKT pathway in obesity and type 2 diabetes[J]. Int J Biol Sci, 2018, 14(11):1483-1496.
[23] Ono H, Pocai A, Wang YH, et al. Activation of hypothalamic S6 kinase mediates diet-induced hepatic insulin resistance in rats[J]. J Clin Invest, 2008, 118(8):2959-2968.
[24] Wang M, Yan WH, Liu Y, et al. Erythropoietin ameliorates diabetes-associated cognitive dysfunction in vitro and in vivo[J]. Sci Rep, 2017, 7(1):2801.
[25] Lu MJ, Wan M, Leavens KF, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1[J]. Nat Med, 2012, 18(3):388-395.
[26] Martinez-Santibañez G, Lumeng CNK. Macrophages and the regulation of adipose tissue remodeling[J]. Annu Rev Nutr, 2014, 34:57-76.
[27] Chen WJ, Wang JL, Luo Y, et al. Ginsenoside Rb1 and compound K improve insulin signaling and inhibit ER stress-associated NLRP3 inflammasome activation in adipose tissue[J]. J Ginseng Res, 2016, 40(4):351-358.
[28] Xu G, Ji C, Song G, et al. miR-26b modulates insulin sensitivity in adipocytes by interrupting the PTEN/PI3K/AKT pathway[J]. Int J Obes (Lond), 2015, 39(10):1523-1530.
[29] Sharma BR, Kim HJ, Rhyu DY.Caulerpa lentillifera extract ameliorates insulin resistance and regulates glucose metabolism in C57BL/KsJ-db/db mice via PI3K/AKT signaling pathway in myocytes[J]. J Transl Med, 2015, 13:62.
[30] Zheng T, Yang XY, Wu D, et al. Salidroside ameliorates insulin resistance through activation of a mitochondria-associated AMPK/PI3K/Akt/GSK3β pathway[J]. Br J Pharmacol, 2015, 172(13):3284-3301.
[31] Wang L, Zhao X, Wei BY, et al. Insulin improves osteogenesis of titanium implants under diabetic conditions by inhibiting reactive oxygen species overproduction via the PI3K-Akt pathway[J]. Biochimie, 2015, 108:85-93.
[32] Kawamura N, Kugimiya F, Oshima Y, et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling[J]. PLoS One, 2007, 2(10):e1058.
[33] Dong K, Hao PJ, Xu S, et al. Alpha-lipoic acid alleviates high-glucose suppressed osteogenic differentiation of MC3T3-E1 cells via antioxidant effect and PI3K/Akt signaling pathway[J]. Cell Physiol Biochem, 2017, 42(5):1897-1906.
[34] Yi SQ, Yu M, Yang S, et al. Tcf12, A member of basic helix-loop-helix transcription factors, mediates bone marrow mesenchymal stem cell osteogenic differentiation in vitro and in vivo[J]. Stem Cells, 2017, 35(2):386-397.
[35] Liu BL, Gan XQ, Zhao YW, et al. Inhibition of HMGB1 promotes osseointegration under hyperglycemic condition through improvement of BMSC dysfunction[J]. Oxid Med Cell Longev, 2019, 2019:1703709.
[36] Zhang Y, Zhang L, Yan M, et al. Inhibition of phosphatidylinosi-tol 3-kinase causes cell death in rat osteoblasts through inactivation of Akt[J]. Biomed Pharmacother, 2007, 61(5):277-284.
[37] Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system[J]. Cardiovasc Res, 2009, 82(2):261-271.
[38] Mourani PM, Garl PJ, Wenzlau JM, et al. Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN[J]. Circulation, 2004, 109(10):1299-1306.
[39] Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis:A crucial target for anti- and pro-angiogenic therapies[J]. Genes Cancer, 2011, 2(12):1097-1105.
[40] Chen JH, Somanath PR, Razorenova O, et al. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo[J]. Nat Med, 2005, 11(11):1188-1196.
[41] Lee MY, Luciano AK, Ackah E, et al. Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates[J]. Proc Natl Acad Sci USA, 2014, 111(35):12865-12870.
[42] Martins BR, Pinto TS, da Costa Fernandes CJ, et al. PI3K/AKT signaling drives titanium-induced angiogenic stimulus[J]. J Mater Sci Mater Med, 2021, 32(1):18.
[43] Ma P, Gu B, Xiong W, et al. Glimepiride promotes osteogenic differentiation in rat osteoblasts via the PI3K/Akt/ENOS pathway in a high glucose microenvironment[J]. PLoS One, 2014, 9(11):e112243.
[44] Ying XZ, Chen XW, Liu HX, et al. Silibinin alleviates high glucose-suppressed osteogenic differentiation of human bone marrow stromal cells via antioxidant effect and PI3K/Akt signaling[J]. Eur J Pharmacol, 2015, 765:394-401.